Progressive myoclonic epilepsy as an adult-onset manifestation of Leigh syndrome due to m.14487T>C

医学 强直性脊柱炎 末端炎 妥珠单抗 内科学 百时美 物理疗法 阿达木单抗 胃肠病学 外科 关节炎 疾病 银屑病性关节炎
作者
Bart Dermaut,Sara Seneca,Lina Dom,Kaat Smets,Luc Ceulemans,Joél Smet,Boél De Paepe,Simon Tousseyn,Sarah Weckhuysen,Marc Gewillig,P. Pals,Paul M. Parizel,Jan De Bleecker,Paul Boon,Linda De Meırleır,Peter De Jonghe,Rudy Van Coster,Wim Van Paesschen,Patrick Santens
出处
期刊:Journal of Neurology, Neurosurgery, and Psychiatry [BMJ]
卷期号:81 (1): 90-93 被引量:33
标识
DOI:10.1136/jnnp.2008.157354
摘要

Background

Axial spondyloarthritis (axSpA) is characterized by inflammation of the spine. However, the disease can also be associated with extra-spinal manifestations such as inflammation of the entheses (enthesitis) and peripheral joints, which can add to the burden of disease. RAPID-axSpA (NCT01087762) is a Phase 3 clinical trial of certolizumab pegol (CZP) in patients (pts) with axSpA including pts with (ankylosing spondylitis [AS]) or without (non-radiographic axSpA [nr-axSpA]) radiographic damage of the sacroiliac joints.1

Objectives

To report the impact of CZP treatment on enthesitis (measured by Maastricht Ankylosing Spondylitis Enthesitis Score [MASES]) and peripheral joint swelling and tenderness.

Methods

The RAPID-axSpA trial was double-blind and placebo (PBO)-controlled to Week (Wk) 24. Pts fulfilled ASAS criteria and had active axSpA. Pts were originally randomized 1:1:1 to either CZP 200mg Q2W, 400mg Q4W (following 400mg loading dose at Wks 0, 2, 4) or PBO. Enthesitis (MASES; count of 0–13 affected sites), swollen joints (SJC; 0–66 joints) and tender joints (TJC; 0–68 joints) were assessed at baseline and at each study visit to Wk24. Data are presented here for the subsets of pts within the Full Analysis Set (FAS) with ≥1 swollen joint, ≥1 tender joint or ≥1 enthesial site affected at baseline. LOCF imputation was used for pts escaping to CZP, withdrawing or having missing measurements. No analyses of statistical significance were carried out on these data.

Results

At baseline, of the 324 pts in the FAS, 229 had enthesitis in ≥1 enthesial site, with a mean MASES score of 5.1; 123 had ≥1 swollen joint, with a mean SJC of 4.2; and 212 had ≥1 tender joint, with a mean TJC of 6.6. Improvements were seen in all three extra-spinal measures following CZP treatment. At Wk24 the mean change from baseline in MASES for CZP-treated pts was -2.9 compared to -0.9 for PBO pts; for SJC the mean change from baseline for CZP pts was -2.8 compared to -0.7 for PBO pts; and for TJC the mean change from baseline for CZP pts was -2.7 compared to -0.4 in PBO pts. Baseline severity of extra-spinal manifestations and improvements observed to Wk24 were similar between the AS and nr-axSpA subpopulations (Table). Improvements were also similar between both CZP dosing regimens (data not shown).

Conclusions

CZP treatment of axSpA patients was associated with a marked improvement in measures of enthesitis and extra-spinal joint inflammation. Similar improvements were seen in both the AS and nr-axSpA subpopulations.

References

Landewé R. Ann Rheum Dis 2014;73:39-47

Acknowledgements

The authors acknowledge Costello Medical Consulting for writing and editorial assistance which was funded by UCB Pharma.

Disclosure of Interest

P. Mease Grant/research support: (Abbott) AbbVie, Amgen, BiogenIdec, BMS, Celgene, Crescendo, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, UCB Pharma, Vertex, Consultant for: (Abbott) AbbVie, Amgen, BiogenIdec, BMS, Celgene, Crescendo, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, UCB Pharma, Vertex, Speakers bureau: (Abbott) AbbVie, Amgen, BiogenIdec, BMS, Crescendo, Genentech, Janssen, Lilly, Pfizer, UCB Pharma, M. Dougados Grant/research support: UCB Pharma, Abbvie, Pfizer, Lilly, Novartis, Consultant for: UCB Pharma, Abbvie, Pfizer, Lilly, Novartis, O. Davies Shareholder of: UCB Pharma, Employee of: UCB Pharma, T. Nurminen Employee of: UCB Pharma, J. Sieper Consultant for: Abbott, Merck, Pfizer, UCB Pharma, Novartis, Lilly, Janssen, Speakers bureau: Abbott, Merck, Pfizer, UCB Pharma, Novartis, Lilly, Janssen

DOI

10.1136/annrheumdis-2014-eular.1558
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
xuan完成签到,获得积分10
1秒前
完美世界应助段一帆采纳,获得10
3秒前
少敏敏完成签到,获得积分10
5秒前
may发布了新的文献求助10
5秒前
10秒前
12秒前
兜兜关注了科研通微信公众号
12秒前
wbh完成签到,获得积分10
13秒前
太牛的GGB发布了新的文献求助10
13秒前
wbh发布了新的文献求助10
15秒前
乐乐应助may采纳,获得10
15秒前
顺利的梦菲完成签到 ,获得积分10
16秒前
777完成签到 ,获得积分10
16秒前
上官若男应助忧郁盼夏采纳,获得10
17秒前
冷艳的姿发布了新的文献求助10
18秒前
量子星尘发布了新的文献求助10
20秒前
21秒前
23秒前
24秒前
时光发布了新的文献求助10
25秒前
26秒前
1111完成签到,获得积分10
27秒前
张怡博发布了新的文献求助10
28秒前
周em12_发布了新的文献求助10
29秒前
29秒前
积极鱼完成签到 ,获得积分10
30秒前
31秒前
研友_VZG7GZ应助无所谓的啦采纳,获得10
31秒前
科研通AI5应助无所谓的啦采纳,获得10
31秒前
田様应助无所谓的啦采纳,获得10
31秒前
多晶1发布了新的文献求助10
33秒前
烟花应助兜兜采纳,获得10
34秒前
35秒前
生椰拿铁发布了新的文献求助10
35秒前
我是老大应助Stroeve采纳,获得10
35秒前
谦让碧菡完成签到,获得积分10
36秒前
CodeCraft应助xingxingxing采纳,获得10
41秒前
大个应助甜甜的悲采纳,获得10
42秒前
43秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989378
求助须知:如何正确求助?哪些是违规求助? 3531442
关于积分的说明 11254002
捐赠科研通 3270126
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173